IMVT-1401 Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving IMVT-1401 Growth

• Strong Phase III efficacy in generalized myasthenia gravis (gMG)

In March 2025, Immunovant announced positive topline Phase III data showing that batoclimab met its primary endpoint in gMG. The higher-dose arm achieved a 5.6-point mean improvement in MG-ADL score with a 93% MG-ADL response rate, while producing approximately 74% mean IgG reduction. The magnitude of clinical benefit was viewed as highly competitive within the FcRn inhibitor class and demonstrated strong correlation between deeper IgG lowering and better clinical outcomes.

• Broad multi-indication autoimmune strategy expands commercial opportunity

IMVT-1401 has shown activity across several large autoimmune indications including CIDP, Graves’ disease, and gMG. In the Phase IIb CIDP study, patients achieving ≥70% IgG reduction demonstrated an 84% responder rate with meaningful improvements in disability scores. Meanwhile, early Graves’ disease studies demonstrated normalization of thyroid hormone levels in a subset of difficult-to-treat patients. This multi-indication applicability significantly broadened the commercial opportunity for FcRn inhibition.

• Validated FcRn inhibitor class substantially reduces scientific risk

The FcRn inhibitor market has become one of the fastest-growing segments in autoimmune therapeutics following approvals of therapies such as Vyvgart and Rystiggo. Batoclimab helped further validate FcRn blockade as an effective strategy for reducing pathogenic IgG antibodies across multiple autoimmune diseases. Published reviews in neurology literature highlighted FcRn inhibition as a major advancement in diseases such as myasthenia gravis because of its rapid onset, targeted mechanism, and broad autoimmune applicability.

• Subcutaneous administration improves patient convenience and scalability

Batoclimab is administered subcutaneously, offering a practical advantage compared with intravenous biologics used in autoimmune diseases. Weekly or biweekly subcutaneous dosing could support home administration, improve adherence, and reduce infusion-center burden. Ease of administration is increasingly important as the FcRn class becomes more competitive and chronic autoimmune diseases require long-term maintenance therapy.

IMVT-1401 Recent Developments

In December 2023, Immunovant reported positive initial Phase 2 results for batoclimab in patients with Graves' disease. 
“IMVT-1401 Sales Forecast, and Market Size Analysis - 2034” report provides comprehensive insights of IMVT-1401 for potential indication like Myasthenia gravis, Graves ophthalmopathy, Idiopathic thrombocytopenic purpura, Autoimmune haemolytic anaemia, Chronic inflammatory demyelinating polyradiculoneuropathy, and Neuromyelitis optica in the 7MM. A detailed picture of IMVT-1401’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the IMVT-1401 for potential indications. The IMVT-1401 market report provides insights about IMVT-1401’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current IMVT-1401 performance, future market assessments inclusive of the IMVT-1401 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of IMVT-1401 sales forecasts, along with factors driving its market.

IMVT-1401 Drug Summary

IMVT-1401 is an investigational fully human monoclonal antibody developed by Immunovant for the treatment of immunoglobulin G (IgG)-mediated autoimmune diseases, including thyroid eye disease (TED), Graves’ disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy (CIDP). The drug targets the neonatal Fc receptor (FcRn), a key regulator of IgG recycling, and works by blocking FcRn-mediated antibody recycling, thereby accelerating degradation of pathogenic IgG autoantibodies involved in autoimmune disease progression. Administered as a subcutaneous injection, IMVT-1401 has demonstrated substantial reductions in circulating IgG and thyroid-stimulating hormone receptor antibodies (TSHR-Ab), supporting its potential disease-modifying effects in autoimmune disorders such as TED and Graves’ disease. Clinical studies have shown encouraging improvements in proptosis, orbital inflammation, and thyroid hormone normalization, although reversible increases in cholesterol and reductions in albumin levels were observed in some trials. While late-stage Phase III TED studies in 2026 did not meet their primary endpoint, the program provided important validation of FcRn inhibition in endocrine autoimmune diseases and informed the development of next-generation FcRn inhibitors such as IMVT-1402. The report provides IMVT-1401’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the IMVT-1401 Market Report

The report provides insights into:

• A comprehensive product overview including the IMVT-1401 MoA, description, dosage and administration, research and development activities in potential indication like Myasthenia gravis, Graves ophthalmopathy, Idiopathic thrombocytopenic purpura, Autoimmune haemolytic anaemia, Chronic inflammatory demyelinating polyradiculoneuropathy, and Neuromyelitis optica.
• Elaborated details on IMVT-1401 regulatory milestones and other development activities have been provided in IMVT-1401 market report.
• The report also highlights IMVT-1401‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The IMVT-1401 market report also covers the patents information, generic entry and impact on cost cut.
• The IMVT-1401 market report contains current and forecasted IMVT-1401 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The IMVT-1401 market report also features the SWOT analysis with analyst views for IMVT-1401 in potential indications.

Methodology

The IMVT-1401 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

IMVT-1401 Analytical Perspective

• In-depth IMVT-1401 Market Assessment

This IMVT-1401 sales market forecast report provides a detailed market assessment of IMVT-1401 for potential indication like Myasthenia gravis, Graves ophthalmopathy, Idiopathic thrombocytopenic purpura, Autoimmune haemolytic anaemia, Chronic inflammatory demyelinating polyradiculoneuropathy, and Neuromyelitis optica in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted IMVT-1401 sales data uptil 2034.

• IMVT-1401 Clinical Assessment

The IMVT-1401 market report provides the clinical trials information of IMVT-1401 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

IMVT-1401 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

IMVT-1401 Market Potential & Revenue Forecast

• Projected market size for the IMVT-1401 and its key indications
• Estimated IMVT-1401 sales potential (IMVT-1401 peak sales forecasts)
• IMVT-1401 Pricing strategies and reimbursement landscape

IMVT-1401 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• IMVT-1401 Market positioning compared to existing treatments
• IMVT-1401 Strengths & weaknesses relative to competitors

IMVT-1401 Regulatory & Commercial Milestones

• IMVT-1401 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

IMVT-1401 Clinical Differentiation

• IMVT-1401 Efficacy & safety advantages over existing drugs
• IMVT-1401 Unique selling points

IMVT-1401 Market Report Highlights

• In the coming years, the IMVT-1401 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The IMVT-1401 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence IMVT-1401’s dominance.
• Other emerging products for Myasthenia gravis, Graves ophthalmopathy, Idiopathic thrombocytopenic purpura, Autoimmune haemolytic anaemia, Chronic inflammatory demyelinating polyradiculoneuropathy, and Neuromyelitis optica are expected to give tough market competition to IMVT-1401 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of IMVT-1401 in potential indications.
• Analyse IMVT-1401 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted IMVT-1401 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of IMVT-1401 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of IMVT-1401? How strong is IMVT-1401’s clinical and commercial performance?
• What is IMVT-1401’s clinical trial status in each individual indications such as Myasthenia gravis, Graves ophthalmopathy, Idiopathic thrombocytopenic purpura, Autoimmune haemolytic anaemia, Chronic inflammatory demyelinating polyradiculoneuropathy, and Neuromyelitis optica and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the IMVT-1401 Manufacturers?
• What are the key designations that have been granted to IMVT-1401 for potential indications? How are they going to impact IMVT-1401’s penetration in various geographies?
• What is the current and forecasted IMVT-1401 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of IMVT-1401 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to IMVT-1401 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is IMVT-1401? What is the duration of therapy and what are the geographical variations in cost per patient?

This product will be delivered within 2 business days.